Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?

J. Andrew Williams, Jack Cook and Susan I. Hurst
Drug Metabolism and Disposition December 2003, 31 (12) 1526-1530; DOI: https://doi.org/10.1124/dmd.31.12.1526
J. Andrew Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Cook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan I. Hurst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Recent research on CYP3A5 in vitro and in humans has provided discordant information on whether CYP3A5 plays a significant role in the metabolism of CYP3A substrates in vivo. For example, six separate studies have reported CYP3A5 to contribute between 2 and 60% of the total hepatic CYP3A. Suggested explanations for the reported differences in hepatic CYP3A5 levels are evaluated in this article. Furthermore, a sensitivity analysis of the contribution of CYP3A5 (in addition to CYP3A4) to the metabolism of a “midazolam”-type substrate based on recently published in vitro and clinical data is compared with the results of two in vivo studies that investigated the influence of CYP3A5 genotype on midazolam pharmacokinetics. The sensitivity analysis predicts an approximately 3-fold lower AUCoral for midazolam for those expressing the highest hepatic and intestinal levels of CYP3A5 (e.g., possessing CYP3A5*1 alleles) compared with those individuals who express insignificant amounts of CYP3A5, assuming CYP3A4 levels are the same in both groups and that CYP3A5 levels do not exceed those of CYP3A4 in CYP3A5*1 homozygotes. In contrast, the two in vivo studies show no statistically significant influence of CYP3A5 genotype on midazolam pharmacokinetics. The discordance between the prediction and the results from the two in vivo studies is discussed.

Footnotes

  • ↵1 Abbreviation used is: P450, cytochrome P450.

  • The question discussed in this article was addressed in part by J.A.W. at the 20th Annual Meeting of the New England Membrane Enzyme Group (NUTMEG) in Salem, Massachusetts, in November 2002.

  • Figure2

  • J. Andrew Williams received a B.S. in Genetics from the University of Wales, Swansea in 1989, a M.S. in Toxicology from the University of Birmingham, England in 1991, and a Ph.D. in Pharmacology (Thesis title: Induction of Cytochrome P4503A—with Professor Gabrielle M. Hawksworth and Dr. Richard Chenery) from the University of Aberdeen, Scotland in 1995. This was followed by postdoctoral research into developmental toxicology (St. George's Hospital, London, with Professor Nigel A. Brown), human breast and prostate carcinogenesis (Institute of Cancer Research/Royal Marsden Hospital, London, with Professor David H. Phillips), and in vitro drug metabolism (Lilly Research Laboratories, Indianapolis, Indiana, with Dr Steven A. Wrighton). In 2001, he joined the Department of Pharmacokinetics, Dynamics and Metabolism at Pfizer Global Research and Development in Ann Arbor, Michigan. His current research interests include ligand interactions with human CYP3A and UGT enzymes and novel approaches to simulate and/or predict metabolic clearance and metabolic drug-drug interactions.

  • Figure3

  • Jack Cook is a Director in the Clinical Pharmacokinetics and Pharmacodynamics Department at Pfizer Global Research and Development, Ann Arbor, Michigan. He received B.S. degrees in Pharmacy and Applied Mathematics from Ferris State College in 1981 and a Ph.D. from the University of Michigan in 1987. Prior to joining Pfizer in 1990, Dr. Cook was a group leader at Sterling Drug, Inc. and served as an adjunct faculty member at Albany College of Pharmacy. His current interests include predicting drug interactions from in vitro data, improving therapy by optimizing drug delivery, and the use of modeling in the development of CNS drugs.

  • Figure4

  • Susan Hurst received her B.S. degree in Pharmacy from Purdue University in 1987. Subsequently, she worked as a staff pharmacist for several years at Ball Memorial Hospital in Muncie, Indiana. She received her Ph.D. from the University of Washington, Seattle in 1999 (Thesis title: Roles of Cytochromes P450 and Microsomal Epoxide Hydrolase in Drug-Drug Interactions Involving Valproic Acid and Its Analogs; Advisor: Rene H. Levy, Ph.D.). This was followed by postdoctoral research at Parke-Davis with Dr. Mike Sinz. In 2000 she joined Pfizer Global Research and Development as a permanent colleague in the Department of Pharmacokinetics, Dynamics, and Metabolism, in Ann Arbor, Michigan. Her current interests include novel approaches for the prediction of in vivo metabolic clearances and drug-drug interactions from in vitro data and extrahepatic metabolism.

    • Received April 2, 2003.
    • Accepted June 4, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (12)
Drug Metabolism and Disposition
Vol. 31, Issue 12
1 Dec 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?

J. Andrew Williams, Jack Cook and Susan I. Hurst
Drug Metabolism and Disposition December 1, 2003, 31 (12) 1526-1530; DOI: https://doi.org/10.1124/dmd.31.12.1526

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?

J. Andrew Williams, Jack Cook and Susan I. Hurst
Drug Metabolism and Disposition December 1, 2003, 31 (12) 1526-1530; DOI: https://doi.org/10.1124/dmd.31.12.1526
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Perspectives on the Predictive Value of in Vitro Data
    • A Sensitivity Analysis for Midazolam Exposure
    • Suggested Explanations for Discordance between Predicted and Observed Data
    • Influence of CYP3A5 Genotype on Cyclosporine Pharmacokinetics or Tacrolimus Dosage Requirements
    • Future Perspectives and Differentiation of CYP3A4 and CYP3A5 in Vivo
    • Appendix: Derivation of Egut Equation
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics